Clinical trials
Carcinoma, Transitional Cell trials in Japan
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
38 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2015 | 3 |
| 2016 | 2 |
| 2017 | 5 |
| 2018 | 3 |
| 2019 | 2 |
| 2020 | 3 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 4 |
| 2025 | 5 |
| 2026 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 19 |
| Recruiting | 12 |
| Terminated | 4 |
| Active, not recruiting | 3 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Eli Lilly and Company | 4 |
| Incyte Corporation | 4 |
| Pfizer | 4 |
| Astellas Pharma Inc | 2 |
| Bayer | 2 |
| Bristol-Myers Squibb | 2 |
| Daiichi Sankyo | 2 |
| Eisai Co., Ltd. | 2 |
| Hoffmann-La Roche | 2 |
| Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carcinoma, Transitional Cell | 38 |
| Urinary Bladder Neoplasms | 14 |
| Carcinoma, Non-Small-Cell Lung | 10 |
| Squamous Cell Carcinoma of Head and Neck | 7 |
| Ovarian Neoplasms | 5 |
| Uterine Cervical Neoplasms | 5 |
| Carcinoma, Hepatocellular | 4 |
| Carcinoma, Renal Cell | 4 |
| Endometrial Neoplasms | 4 |
| Melanoma | 4 |
Trials
Showing 76 to 38 of 38. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.